StreetInsider.com News Articles

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 07:30:00 -0400

CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On September 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 7,200 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 07:30:00 -0400

Form 4 ABEONA THERAPEUTICS INC. For: Sep 29 Filed by: Seshadri Vishwas

Tue, 29 Sep 2026 21:49:00 -0400

si-local-file:///var/storage/secattach/20260929/27123859.html

Form 4 ABEONA THERAPEUTICS INC. For: Sep 29 Filed by: Vazzano Joseph Walter

Tue, 29 Sep 2026 21:48:00 -0400

si-local-file:///var/storage/secattach/20260929/27123858.html

Form 4 ABEONA THERAPEUTICS INC. For: Sep 29 Filed by: O'Malley Brendan M.

Tue, 29 Sep 2026 21:48:00 -0400

si-local-file:///var/storage/secattach/20260929/27123857.html

Form 4 ABEONA THERAPEUTICS INC. For: Sep 29 Filed by: Vasanthavada Madhav

Tue, 29 Sep 2026 21:48:00 -0400

si-local-file:///var/storage/secattach/20260929/27123856.html

Form 144 ABEONA THERAPEUTICS INC. Filed by: Vazzano Joseph Walter

Tue, 29 Sep 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260929/27123206.html

Form 144 ABEONA THERAPEUTICS INC. Filed by: Seshadri Vishwas

Tue, 29 Sep 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260929/27123140.html

Form 144 ABEONA THERAPEUTICS INC. Filed by: Vasanthavada Madhav

Tue, 29 Sep 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260929/27123137.html

Form 144 ABEONA THERAPEUTICS INC. Filed by: O'Malley Brendan M.

Tue, 29 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260929/27123122.html

H.C. Wainwright Reiterates Buy Rating on Abeona Therapeutics (ABEO)

Fri, 25 Sep 2026 06:50:24 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $20.00 price target on Abeona Therapeutics (NASDAQ: ABEO).

The analyst commented: "FAYUVI approval slated to yield potentially sizable rewards in the form of royalties and commercial milestone payments. Abeona recently noted the September 17 FDA approval of FAYUVI (rebisufligene etisparvovec-hopf), also known as UX111, a gene therapy for the treatment of patients with Sanfilippo syndrome type A (mucopolysaccharidosis IIIA, or MPS IIIA), a rare and progressive neurodegenerative lysosomal storage disorder. FAYUVI originated from pioneering research conducted by Drs. Haiyan Fu and Douglas McCarty at The Ohio State University and Nationwide Children's

FDA approves Ultragenyx gene therapy originally developed by Abeona

Fri, 18 Sep 2026 07:30:14 -0400

The U.S. Food and Drug Administration approved FAYUVI (rebisufligene etisparvovec-hopf), a gene therapy for Sanfilippo syndrome type A (MPS IIIA), a rare and progressive neurodegenerative disorder in children. Ultragenyx Pharmaceutical holds global development and commercialization rights to the therapy.

FAYUVI originated from research conducted by Drs. Haiyan Fu and Douglas McCarty at The Ohio State University and Nationwide Children's Hospital. Abeona Therapeutics (Nasdaq: ABEO) advanced the program through preclinical and early clinical development under the name ABO-102 before out-licensing it to Ultragenyx in May 2022.

The therapy delivers a functional copy of the SGSH gene to the central nervous system via an

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Fri, 18 Sep 2026 07:30:00 -0400

- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts -

- Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families -

CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultragenyx Pharmaceutical Inc., on the U.S. Food and Drug Administration (FDA) approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, a gene therapy for the

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Fri, 18 Sep 2026 07:30:00 -0400

- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts -

- Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families -

Abeona Therapeutics (ABEO) PT Raised to $30 at Cantor Fitzgerald on FAYUVI Approval

Fri, 18 Sep 2026 06:57:55 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Abeona Therapeutics (NASDAQ: ABEO) to $30.00 (from $28.00) while maintaining an Overweight rating.

The analyst commented, "Today, 9/17, Abeona's partner Ultragenyx announced the approval of FAYUVI (UX111, AAV9-based gene therapy) for Sanfilippo syndrome Type A (MPS IIIA). As part of this agreement, Ultragenyx assumed responsibility across development, manufacturing and commercialization, with ABEO eligible for tiered royalties of up to 10% on net sales and commercial milestone payments up to $30M. Following this news, we are raising our PT to $30 from $28 prior."

Abeona Therapeutics (ABEO) PT Raised to $30 at Cantor Fitzgerald on FAYUVI Approval

Fri, 18 Sep 2026 06:57:55 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Abeona Therapeutics (NASDAQ: ABEO) to $30.00 (from $28.00) while maintaining an Overweight rating.

Roth/MKM Starts Abeona Therapeutics (ABEO) at Buy

Thu, 17 Sep 2026 02:52:29 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ: ABEO) with a Buy rating and a price target of $17.00.

The analyst comments: “We initiate coverage of ABEO with a Buy rating and 12-month PT of $17. Our bullish view is predicated upon ZEVASKYN’s durable profile targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB)—a rare skin disease. Despite carrying a $3.1M price tag, ZEVASKYN has drawn no payor denials to date and is being implemented at 8/10 Qualified Treatment Center (QTC) U.S. sites. Our models estimate ABEO achieves GAAP net income profitability in 1Q27 and >$275M in sales in 2029. Should an

Roth/MKM Starts Abeona Therapeutics (ABEO) at Buy

Thu, 17 Sep 2026 02:52:29 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ: ABEO) with a Buy rating and a price target of $17.00.

Abeona adds UF Health as 8th treatment center for Zevaskyn

Wed, 16 Sep 2026 07:31:19 -0400

Abeona Therapeutics (Nasdaq: ABEO) announced that University of Florida Health in Gainesville, Florida, has been activated as the eighth Qualified Treatment Center for administering Zevaskyn (prademagene zamikeracel), a gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB).

UF Health is described in the company's statement as the only treatment center for Zevaskyn in the Southeastern United States. The facility has begun patient identification and onboarding activities.

Zevaskyn is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with RDEB, a rare genetic skin disorder in which patients cannot produce functional type VII collagen,

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

Wed, 16 Sep 2026 07:30:00 -0400

CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

“Activation of UF Health as a QTC represents an important step in expanding access to

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

Wed, 16 Sep 2026 07:30:00 -0400

“Activation of UF Health as a QTC represents an important step in expanding access to

Form 8-K ABEONA THERAPEUTICS INC. For: Sep 15

Tue, 15 Sep 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260915/27063667.html

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:30:00 -0400

CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:

Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.
H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.
Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat on Wednesday, September 16, 2026, at

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:30:00 -0400

Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.
H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.
Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat on Wednesday, September 16, 2026, at

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 07:30:00 -0400

CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On August 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,300 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards